U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07296042) titled 'Targeted And Perilesional Or Systematic Biopsy In Prostate Cancer' on Nov. 14.
Brief Summary: Magnetic Resonance Imaging (MRI) improves the detection of clinically significant prostate cancer (PCa) by guiding biopsies of MRI-visible lesions (targeted biopsies) in patients suspected with having PCa. This strategy increases the detection of clinically significant PCa, however, while also increasing the detection of insignificant prostate cancer, often synonymous of "overdiagnosis".
It is well known that insignificant PCa has a very low risk of local and distant progression, and active surveillance with a deferred curative treatment p...